Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug

Dow Jones

01/14

By Joe Stonor

Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner.

Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index.

Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally.

Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added.

Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros.

The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros.

Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.K. and the European Union.

Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close.

Write to Joe Stonor at josephmichael.stonor@wsj.com

(END) Dow Jones Newswires

January 14, 2026 09:02 ET (14:02 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603611422"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603611422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603611422?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603611422","market":"nz","top_or_hot":-1,"title":"Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joe Stonor \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n</p>\n<p>\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n</p>\n<p>\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n</p>\n<p>\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n</p>\n<p>\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n</p>\n<p>\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n</p>\n<p>\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and the European Union. \n</p>\n<p>\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBayer Shares Surge as Partner Forecasts Sales Growth for Prostate-Cancer Drug\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-14 22:02</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joe Stonor \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n</p>\n<p>\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n</p>\n<p>\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n</p>\n<p>\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n</p>\n<p>\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n</p>\n<p>\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n</p>\n<p>\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. and the European Union. \n</p>\n<p>\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 09:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BAYRY","symbol_name":"Bayer A.G.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603611422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603611422","pubTimestamp":1768399320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner.Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index.Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally.Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros  in the future, it added.Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros.The company hasn't released 2025 earnings, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BAYRY":"Bayer A.G.","BK4007":"制药"},"translate_title":"合作伙伴预测前列腺癌药物销售增长，拜耳股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BAYRY":0.9},"content_text":"By Joe Stonor \n\n\n \n\n\n  Shares in Bayer jumped 6% after Finnish pharmaceutical company Orion predicted strong growth for darolutamide, a prescription prostate-cancer medication on which the two companies partner. \n\n\n  Bayer stock gained 5.8%, or 2.26 euros, to 41.2 euros in early afternoon European trading Wednesday. Shares in Orion also leapt on the announcement, gaining 12%. The Helsinki-listed company is the biggest riser in the Europe-wide Stoxx 600 index. \n\n\n  Bayer and Orion partnered in 2014 to develop darolutamide, with Bayer funding development while Orion handled the drug's manufacturing. Bayer is responsible for taking the drug to market globally. \n\n\n  Darolutamide is Orion's biggest drug by far and its main profit-driver, the company said. Sales of the drug could exceed 1 billion euros ($1.16 billion) in the future, it added. \n\n\n  Orion guided for net group sales for this year of between 1.9 billion euros and 2.1 billion euros and for operating profit of 550 million euros to 750 million euros. \n\n\n  The company hasn't released 2025 earnings, which are due on Feb. 12. It previously guided for 2025 net sales of between 1.64 billion euros and 1.72 billion euros and for operating profit of 410 million euros to 490 million euros. \n\n\n  Darolutamide, which is sold under the brand name Nubeqa, is approved for use in the U.S., U.K. and the European Union. \n\n\n  Bayer shares are trading at a two-year high after rising steadily since last fall. The company's stock is up more than 40% in the three months to Tuesday's close. \n\n\n \n\n\n  Write to Joe Stonor at josephmichael.stonor@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 09:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}